What truly separates BSEM is its clinically validated BioREtain®
technology ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏
_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Huge Alerts._
-------------------------
[BSEM] [[link removed]]
BSEM JUST PROVED PROFITABILITY IS NOT A FLUKE—SEVEN STRAIGHT WINNING
QUARTERS, CLINICAL DOMINANCE, AND A POTENTIAL NASDAQ MOVE ARE PUTTING
THIS MEDTECH NAME ON THE RADAR FOR 2026
BioStem Technologies (BSEM) [[link removed]] is
doing what most small-cap MedTech companies never achieve: delivering
consistent profitability while scaling adoption in a massive,
underpenetrated market.
Q3 2025 marked BSEM’s seventh consecutive quarter of positive
adjusted EBITDA, alongside $10.5 million in revenue and $0.8 million
in GAAP net income. Backed by $27.2 million in cash and
industry-leading gross margins, the company has shown it can navigate
reimbursement shifts without sacrificing financial discipline—an
increasingly rare trait in regenerative medicine.
What truly separates BSEM is its clinically validated BioREtain®
technology, supported by Level 1 randomized trial data showing
dramatically better outcomes than standard of care in diabetic foot
ulcers.
With expansion underway into the VA, Medicaid, hospitals, and
ASCs—and a Nasdaq uplisting targeted for mid-2026—BioStem is
positioning itself for greater institutional visibility and market
re-rating. Add in a $25.50 Zacks price target, and this looks less
like speculation and more like a company entering its next growth
phase.
Start your due diligence now and decide whether BSEM belongs on your
MedTech watchlist as 2026 catalysts unfold
[[link removed]]
We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists
of up to $6,500 and was received/will be received from Sideways
Frequency.
This compensation should not be considered as an endorsement of the
securities of BioStem Technologies Inc. (OTC: BSEM) and we are not
responsible for any errors or omissions in any information provided
about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge
Alerts.
We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.
This disclosure is made as of 01/06/2026.
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]
Behind the Markets
[[link removed]]
_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._
